// App-Quantinova.ai

4693 : Mechanism-based combination strategies for BET inhibitors in NUT midline carcinoma

Researchers

Presenter

  • Anastasia Wyce

Principal Investigators

  • Peter Soden

  • Daniel J. Felitsky

  • Jeanne J. Matteo

  • Susan Korenchuk

  • Gary Thripp

  • Kathryn Keenan

  • Charles F. McHugh

  • Rab Prinjha

  • Christopher Carpenter

  • Nicholas Smithers

  • Olena Barbash

Medical Centers

  • GlaxoSmithKline, Collegeville, PA

  • GlaxoSmithKline, Stevenage, United Kingdom.

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • NUT midline carcinoma

  • Squamous cell carcinoma

  • Solid malignancies

Biomarkers

  • cMYC

Drug/Treatment

  • I-BET151

  • Molibresib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved